Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totaling 25,053 shares, a drop of 65.5% from the August 15th total of 72,693 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 17,420 shares, the short-interest ratio is presently 1.4 days.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PHAR shares. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Canaccord Genuity Group boosted their target price on Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $38.67.

Institutional Investors Weigh In On Pharming Group

Hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC purchased a new position in Pharming Group during the 2nd quarter valued at about $32,000. SmartHarvest Portfolios LLC purchased a new stake in shares of Pharming Group in the fourth quarter worth approximately $224,000. Millennium Management LLC acquired a new stake in shares of Pharming Group during the fourth quarter worth approximately $360,000. Finally, NewEdge Advisors LLC grew its position in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares in the last quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Stock Up 3.7%

PHAR stock opened at $11.21 on Friday. Pharming Group has a 52-week low of $9.62 and a 52-week high of $21.34. The company’s 50 day simple moving average is $12.07 and its 200-day simple moving average is $13.86. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. The firm has a market capitalization of $793.42 million, a P/E ratio of 93.42 and a beta of 0.01.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. As a group, equities research analysts anticipate that Pharming Group will post 0.25 EPS for the current year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.